Madrigal Pharmaceuticals Inc.
MDGL | NASDAQ
$521.96
-$9.56 (-1.80%)
At close: Sep 21, 2026, 4:00 PM ET
$521.96
$0 (0.00%)
After-hours:
Sep 21, 2026, 7:30 PM ET
Company Profile
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| William J. Sibold | Chief Executive Officer, President & Director |
| Mardi C. Dier | Executive Vice President & Chief Financial Officer |
| Ronald Filippo | Executive Vice President & Chief Information Officer |
| Shannon Kelley | Executive Vice President, Chief Legal Officer & Corporate Secretary |
| Carole Huntsman | Executive Vice President & Chief Commercial Officer |
| David Soergel | Executive VP & Chief Medical Officer |
| Mark Underwood | Executive Vice President of Business Planning & Operations |
| Rebecca A. Taub | Founder, Senior Scientific & Medical Advisor and Director |
| Rita Thakkar | Senior VP & Chief Accounting Officer |
| Tina E. Ventura | Chief Investor Relations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 3 | Filing |
| Aug 12, 2026 | 8-K | Current Report |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 20, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
| Jun 18, 2026 | 4 | Filing |
Madrigal Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Feb 5, 2007 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 915 |
| CEO | William J. Sibold |
Contact Details
1001 Conshohocken State Road West Conshohocken,
Pennsylvania 19428 United States
Stock Details
| Ticker Symbol | MDGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001157601 |
| CUSIP Number | 558868105 |
| ISIN Number | US5588681057 |
| SIC Code | 2834 |
Recent News
- 12 days ago / seekingalpha.comMadrigal Pharmaceuticals, Inc. (MDGL) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
- 12 days ago / fool.comInstitutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You?
- 28 days ago / fool.comHere's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off
- 1 month ago / defenseworld.netMadrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
- 1 month ago / globenewswire.comMadrigal Appoints John C. Reed, M.D.
- 1 month ago / seekingalpha.comMadrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
- 2 months ago / globenewswire.comMadrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
- 2 months ago / zacks.comMDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
- 2 months ago / marketbeat.comMadrigal Pharmaceuticals Q2 Earnings Call Highlights
- 2 months ago / seekingalpha.comMadrigal Pharmaceuticals, Inc. (MDGL) Q2 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove MDGL